Starpharma's anti HIV gel makes it into the Financial Times along with an overview of Australian nanotech. The conclusion so far is that “Australia is getting really good value for the money we've invested because of the high success rate in this market of introducing everyday products.”
Good on yer, mates.
Posted by Cientifica at November 4, 2004 11:16 AM | TrackBack